New Releases from NCBI BookshelfCannabidiol (Epidiolex): CADTH Reimbursement Recommendation: Indication: Use as adjunctive therapy for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age and older [Internet].​Cannabidiol (Epidiolex): CADTH Reimbursement Recommendation: Indication: Use as adjunctive therapy for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age and older [Internet].

By /

CADTH recommends that Epidiolex be reimbursed by public drug plans for the adjunctive therapy of seizures associated with Dravet syndrome (DS) in patients aged 2 years or older, if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top